| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1048858360 |
| P356 | DOI | 10.1038/SJ.GT.3302942 |
| P698 | PubMed publication ID | 17429445 |
| P5875 | ResearchGate publication ID | 6399901 |
| P2093 | author name string | Shah AC | |
| Markert JM | |||
| Lakeman FD | |||
| Gillespie GY | |||
| Parker JN | |||
| Cassady KA | |||
| Meleth S | |||
| P2860 | cites work | Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model | Q37141874 |
| The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors | Q37247954 | ||
| Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants | Q37693154 | ||
| Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. | Q40219504 | ||
| Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. | Q40707342 | ||
| Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection | Q42589554 | ||
| Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture | Q44460699 | ||
| Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine | Q44617972 | ||
| Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus | Q45745964 | ||
| Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central n | Q45760662 | ||
| Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant | Q45854779 | ||
| An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor | Q48945443 | ||
| Confidence intervals for the survival function using Cox's proportional-hazard model with covariates | Q70407302 | ||
| Intergeneric poliovirus recombinants for the treatment of malignant glioma | Q24682902 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells | Q33755158 | ||
| Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her | Q33780588 | ||
| The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha | Q33783719 | ||
| A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals | Q33851852 | ||
| Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma | Q33905047 | ||
| Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial | Q33905053 | ||
| The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study | Q34124333 | ||
| ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties | Q34178661 | ||
| Second-site mutation outside of the U(S)10-12 domain of Deltagamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence | Q34328502 | ||
| Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins | Q34463480 | ||
| Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma | Q34616722 | ||
| Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence | Q34779144 | ||
| Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors | Q35051285 | ||
| Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells | Q35131235 | ||
| Tumor specific activation of PKR as a non-toxic modality of cancer treatment | Q35561619 | ||
| Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model | Q35800497 | ||
| Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology | Q35939662 | ||
| Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. | Q35945465 | ||
| The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA- | Q35964369 | ||
| Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects | Q36402863 | ||
| The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells | Q36945982 | ||
| Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells | Q37116149 | ||
| P433 | issue | 13 | |
| P921 | main subject | oncolytic virus | Q1560099 |
| P304 | page(s) | 1045-1054 | |
| P577 | publication date | 2007-04-12 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses | |
| P478 | volume | 14 |
| Q37679389 | A systematic approach to virus-virus interactions. |
| Q38966483 | Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines |
| Q45323639 | Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory |
| Q36849213 | Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors. |
| Q36142487 | Designing Herpes Viruses as Oncolytics |
| Q35867997 | Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors |
| Q37564490 | Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways |
| Q33713824 | Herpes simplex virus oncolytic therapy for pediatric malignancies |
| Q34091990 | Herpesvirus vectors for therapy of brain tumors |
| Q33523284 | Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice |
| Q35077031 | Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo |
| Q37533665 | Oncolytic viral therapy of malignant glioma |
| Q36644898 | Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy |
| Q37718569 | Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. |
| Q37882608 | Rethinking herpes simplex virus: the way to oncolytic agents |
| Q38793802 | STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells |
| Q37945174 | Spontaneous and Engineered Compensatory HSV Mutants that Counteract the Host Antiviral PKR Response |
| Q52671217 | Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. |
| Q92003161 | Tumor Control by Cytomegalovirus: A Door Open for Oncolytic Virotherapy? |
| Q51846287 | Tumor Restrictions to Oncolytic Virus. |
| Q36967306 | Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application |
| Q39445325 | Δγ₁134.5 herpes simplex viruses encoding human cytomegalovirus IRS1 or TRS1 induce interferon regulatory factor 3 phosphorylation and an interferon-stimulated gene response |
| Q35251719 | γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia |
Search more.